Recent news on Sanctura

Indevus to Present at the 2007 FBR Growth Conference  -  May 23, 2007
Earthtimes.orgThe Company's marketed products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat male

Alkermes and Indevus Announce Initiation of Phase 2a Clinical ...  -  26 Apr 2007
PipelineReview.com (press release),SANCTURA(R) is Indevus' registered trademark that is assigned in the US to Esprit Pharma Holding Company (subject to our co-exclusive right to use it) and

Indevus Announces Submission of Supplemental NDA to Reintroduce ...  -  Apr 19, 2007
PipelineReview.com (press release),The Company's marketed products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat male

Indevus and Valera Announce Completion of Merger  -  Apr 18, 2007
PharmaLive.com (press release),The Company's marketed products include SANCTURA(R) for overactive bladder, which it co-promotes with its partner Esprit Pharma, Inc. and DELATESTRYL(R) to

Indevus to Present at CIBC Annual Biotechnology & Specialty ...  -  Apr 5, 2007
PR-Inside.com (Pressemitteilung),The compounds in development include SANCTURA XR(TM), the once-daily formulation of SANCTURA, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention

Valera Pharmaceuticals, Inc. Announces Intention to Delist From ...  -  Apr 6, 2007
Web Services Journal,The Company's marketed products include SANCTURA® for overactive bladder and DELATESTRYL® to treat male hypogonadism. The compounds in development include

Indevus Pharmaceuticals "strong buy"  -  Apr 12, 2007
newratings.comAmong the drug class, Indevus Pharmaceuticals’ Sanctura drug has exhibited the lowest rate of CNS side effects, JMP Securities adds. Sanctura currently has

FDA Recommends Precautions for Children and Elderly Taking Ditropan  -  Apr 13, 2007
Associated Content,Oral medications, such as Detrol, Sanctura, and Vesicare are options. Oxytrol, a oxybutynin transdermal system, or skin patch, is another choice.

Biotech Day In Review: MedImmune Puts Itself Up For Sale  -  Apr 12, 2007
Seeking Alpha,Indevus markets Sanctura for overactive bladder, Delatestryl for male hypgogonadism and other drugs. Valera is developing hydrogel-based implants for

Indevus Reports That Interim Review of NEBIDO(R) Phase III Data ...  -  27 Mar 2007
PipelineReview.com (press release),The Company's marketed products include SANCTURA(R) for overactive bladder, which it co-promotes with its partner Esprit Pharma, Inc. and DELATESTRYL(R) to

Bladder condition could be up in smoke  -  Mar 18, 2007
Worcester Business Journal,It is best known for Sanctura, a treatment for overactive bladder. The company doesn't necessarily go after unproven drug discoveries.

Indevus Pharmaceuticals Announces First Quarter Fiscal 2007 ...  -  Feb 7, 2007
PharmaLive.com (press release),The completion of the acquisition, coupled with the planned filing of our NDA for NEBIDO(R) and the pending approval of SANCTURA XR(TM), position 2007 to be

Indevus Pharmaceuticals To Announce First Quarter Fiscal 2007 ...  -  Feb 1, 2007
PR Newswire (press release),The Company's marketed products include SANCTURA(R) for overactive bladder, which it co-promotes with its partner Esprit Pharma, Inc. and DELATESTRYL(R) to

Biotech Roundup: Pfizer's Fesoterodine, NCI/FDA Conference  -  Feb 9, 2007
Minyanville.com,This company and partner Esprit Pharma (private) will launch best-in-class Sanctura XR just after Labor Day this year – assuming the FDA approves the drug

Indevus Pharmaceuticals sees revenue boost  -  Feb 7, 2007
Bizjournals.com,Among its products: Sanctura , a treatment for overactive bladder. Other compounds are in development to treat male hypogonadism, HIV, stuttering and fungal

Punk Ziegel Starts Indevus Pharmaceuticals (IDEV) at Buy  -  Feb 5, 2007
StreetInsider.com (subscription),...is derived from two late-stage drugs, Sanctura XR and Nebido, with best-in-class potential and the pending acquisition of Valera Pharmaceuticals."

FDA Accepts New Drug Application For SANCTURA XR(TM) Submitted By ...  -  Dec 25, 2006
Medical News Today (press release),The FDA Prescription Drug User Fee Act (PDUFA) target action date for SANCTURA XR is August 13, 2007. The NDA was submitted to the FDA by the Company on

Alkermes and Indevus Announce Joint Collaboration to Develop ...  -  Jan 5, 2007
PipelineReview.com (press release),Trospium chloride is the active ingredient in SANCTURA®, Indevus’ currently marketed product for overactive bladder. The formulation under development for

Biotech Stocks Day-in-Review: BioCryst Gets Flu Drug Support  -  Jan 5, 2007
Seeking Alpha,The Indevus drug, marketed as Sanctura for overactive bladder, is trospium chloride, a muscarinic receptor antagonist that relaxes smooth muscle tissue.

FDA Accepts New Drug Application For SANCTURA XR(TM) Submitted By ...  -  Dec 25, 2006
Medical News Today (press release),IDEV) today announced that the US Food and Drug Administration (FDA) has accepted for review the Company's New Drug Application (NDA) for SANCTURA XR (trospium ...

Indevus files for OK of Sanctura XR  -  Dec 13, 2006
United Press International13 (UPI) -- Indevus said Wednesday it submitted a new drug application for Sanctura XR for overactive bladder to the US Food and Drug Administration. ...

Indevus Pharmaceuticals Announces Fiscal 2006 Year End and Fourth ...  -  Dec 7, 2006
Yahoo! News (press release)..."The tremendous results from our SANCTURA XR(TM) Phase III clinical program and our subsequent NDA filing set the stage for an exciting product launch in 2007. ...

Indevus Pharmaceuticals to Acquire Valera Pharmaceuticals  -  Dec 12, 2006
Yahoo! News (press release)Valera's products fit extremely well with our current focused portfolio of marketed and late stage products, including SANCTURA® and SANCTURA XR(TM) for ...

Market Report -- In Play (IDEV)  -  Dec 13, 2006
MSN MoneyIndevus Pharm announces FDA accepts New Drug Application for Sanctura XR submitted by Indevus Co announces that that the US FDA has accepted for review the ...

Indevus Pharmaceuticals to Announce Fiscal 2006 Financial Results ...  -  Dec 5, 2006
Earthtimes.orgThe Company currently co-promotes SANCTURA(R) for overactive bladder and markets DELATESTRYL(R) to treat male hypogonadism and currently has six compounds in ...

Indevus Buyout of Valera to Grow Earnings  -  Dec 18, 2006
Seeking Alpha,...royalties from Lilly (LLY) for Sarafem, prescribed to treat symptoms associated with pre-mentrual syndrome, and copromotes (with Espirit) Sanctura to treat ...

Indevus and Sanofi-Aventis' Spin-Out Company, Novexel, Announce ...  -  Dec 5, 2006
Yahoo! News (press release)The Company currently co-promotes SANCTURA® for overactive bladder and markets DELATESTRYL® to treat male hypogonadism and currently has six compounds in ...

Indevus Pharmaceuticals Posted Modest Gains On SANTURA XR News  -  Dec 13, 2006
Trading Markets,Massachusetts, on Wednesday said Wednesday that the US Food and Drug Administration has accepted for review its New Drug Application for SANCTURA XR or ...

Indevus Pharmaceuticals (IDEV) Misses Q4 EPS by 2c  -  Dec 7, 2006
StreetInsider.com (subscription),Fiscal 2006 revenue consisted primarily of $15.0 million of revenues received in connection from product sales of SANCTURA to the Company's partner, $13.4 ...

Indevus To Acquire Valera For $120 Mln In Stock Transaction Plus ...  -  Dec 12, 2006
Trading Markets,Valera's products fit extremely well with our current focused portfolio of marketed and late stage products, including Sanctura and Sanctura XR for overactive ...

Indevus Pharmaceuticals reports fourth-quarter results  -  Dec 7, 2006
Boston Globe,Indevus has been testing Sanctura XR for overactive bladder and Nebido, a long-acting injectable therapy for male hypogonadism, a condition caused by reduced ...

Indevus ends fiscal year with 50 percent revenue boost  -  Dec 7, 2006
Boston Business Journal,...hypogonadism. Indevus has also generated positive late-stage clinical trial data for Sanctura XR, a drug for overactive bladder. ...

Valera Jumps on Buyout Deal  -  Dec 12, 2006
BusinessWeekIn October the company filed a new drug application with the US Food and Drug Administration for a once a day administration formulation of Sanctura, its drug ...

Sección internacional  -  Dec 13, 2006
Bolsamania.com,...program acceptance ... [+. PRN) - FDA Accepts New Drug Application for SANCTURA XR(TM) Submitted by Indevus ... [+. PRN) - Vion ...

Valera Pharmaceuticals Acquired in $120 Million Stock Deal  -  Dec 12, 2006
Business New Jersey (subscription),Its products include Vantas for the treatment of advanced prostate cancer. Indevus makes drugs such as Sanctura, which is a treatment for overactive bladder. ...

Indevus sees net loss remaining in mid-teens for next few qrtrs  -  Dec 7, 2006
Reuters...the $10 million milestone payment it received from Esprit Pharma for filing a New Drug Application for Indevus' treatment for overactive bladder Sanctura XR. ...

Indevus Pharmaceuticals "strong buy," target price raised  -  Dec 8, 2006
newratings.comFY07, FY09 and FY10 have been raised from -$0.76 to -$0.68, from -$0.55 to -$0.35 and from $0.54 to $0.62, respectively, to reflect higher Sanctura XR-related ...

Indevus Licenses Antifungal To Sanofi Unit Through $44M Deal  -  Dec 7, 2006
Therapeutics Daily (subscription) (press release),...into the company to move forward.? Since then, however, the firm gained FDA approval for its overactive bladder drug, Sanctura, ...

Indevus Pharmaceuticals Scheduled to Present at the UBS Global ...  Sep 20, 2006
The Company currently co-promotes SANCTURA(R) for overactive bladder and markets DELATESTRYL(R) to treat male hypogonadism and currently has six compounds in ... -Business Wire

Overactive Bladder Drugs Only Modestly Effective  Sep 10, 2006
...of the five drugs - oxybutynin (Ditropan, Ditropan XL and Oxytrol, a skin patch); tolterodine (Detrol, Detrol LA); trospium (Sanctura); solifenacin (Vesicare ... -HealthNewsDigest.com

Top Public and Private Biotech Deals  Sep 18, 2006
The company focuses on treatments for urological disorders and ailments that affect women. It main product, Sanctura, treats overactive bladder. ... -Business New Jersey (subscription)

Health Highlights: Sept. 6, 2006  Sep 6, 2006
...of the five drugs -- oxybutynin (Ditropan, Ditropan XL and Oxytrol, a skin patch); tolterodine (Detrol, Detrol LA); trospium (Sanctura); solifenacin (Vesicare ... -Forbes

Indevus Pharmaceuticals initiated with "buy"  Sep 8, 2006
In a research note published yesterday, the analyst mentions that the company is likely to launch two "best in class" drugs, SANCTURA XR and NEBIDO in 2007 and ... -newratings.com

Update on hot topics in DC  Aug 31, 2006
The latest are Lexxel and Tarks, combination drugs to treat hypertension, Lyrica to treat neuropathic pain, and Detrol, Oxytrol and Sanctura to treat ... -The Dolphin

Indevus Pharmaceuticals to Acquire Valera Pharmaceuticals  -  12 Dec 2006
Drug Newswire (press release),Valera's products fit extremely well with our current focused portfolio of marketed and late stage products, including SANCTURA(R) and SANCTURA XR(TM) for

Indevus and Sanofi-Aventis' Spin-Out Company, Novexel, Announce ...  -  Dec 6, 2006
PharmaLive.com (press release),The Company currently co-promotes SANCTURA(R) for overactive bladder and markets DELATESTRYL(R) to treat male hypogonadism and currently has six compounds

Indevus Pharmaceuticals (IDEV) Misses Q4 EPS by 2c  -  Dec 7, 2006
StreetInsider.com (subscription),Fiscal 2006 revenue consisted primarily of $15.0 million of revenues received in connection from product sales of SANCTURA to the Company's partner,

Indevus Pharmaceuticals "strong buy," target price raised  -  Dec 8, 2006
newratings.com...have been raised from -$0.76 to -$0.68, from -$0.55 to -$0.35 and from $0.54 to $0.62, respectively, to reflect higher Sanctura XR-related royalties.

Indevus sees net loss remaining in mid-teens for next few qrtrs  -  Dec 7, 2006
Reuters...million milestone payment it received from Esprit Pharma for filing a New Drug Application for Indevus' treatment for overactive bladder Sanctura XR.

Indevus ends fiscal year with 50 percent revenue boost  -  Dec 7, 2006
Boston Business Journal,Indevus has also generated positive late-stage clinical trial data for Sanctura XR, a drug for overactive bladder. Indevus raised $35 million in July

Indevus Pharmaceuticals reports fourth-quarter results  -  Dec 7, 2006
Boston Globe,Indevus has been testing Sanctura XR for overactive bladder and Nebido, a long-acting injectable therapy for male hypogonadism, a condition caused by

Indevus Licenses Antifungal To Sanofi Unit Through $44M Deal  -  Dec 7, 2006
Therapeutics Daily (subscription) (press release),...focus in bringing drugs into the company to move forward.? Since then, however, the firm gained FDA approval for its overactive bladder drug, Sanctura,

Indevus Announces Third Quarter Fiscal 2006 Financial Results  Aug 3, 2006
..."The positive results of our SANCTURA XR and ... The Company announced positive results from the two Phase III trials for SANCTURA XR(TM) in overactive bladder. ... -Genetic Engineering News

Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2006 ...  Jul 31, 2006
The Company currently co-promotes SANCTURA(R) for overactive bladder and markets DELATESTRYL(R) to treat male hypogonadism and currently has six compounds in ... -Genetic Engineering News

Indevus Pharmaceuticals "hold," estimates reduced  Aug 10, 2006
In a research note published yesterday, the analysts mention that the estimates for the future sales of SANCTURA and SANCTURA XR have been revised in view of ... -newratings.com

Indevus Q3 revenue improves as losses spike  Aug 3, 2006
Indevus said its revenue grew thanks in part to improved sales of Sanctura, its overactive bladder treatment and sales of Delatestryl, which treats male ... -Boston Business Journal

Supporting Corps D’Esprit  Aug 5, 2006
Esprit Pharma’s focus is women’s health and urology, and its key product is Sanctura, a formula for urinary incontinence recently approved by the FDA and ... -Red Herring

Drugmaker raises $90.8M in venture capital  Aug 2, 2006
Esprit's primary drug, a poten tial blockbuster called Sanctura for overactive bladder, places the company in head-to-head competition with pharmaceutical ... -Newark Star Ledger



Indevus Pharmaceuticals Scheduled to Present at Rodman & Renshaw ...  May 11, 2006
The Company currently markets SANCTURA(R) for overactive bladder and DELATESTRYL(R) for the treatment of male hypogonadism. The ... - Genetic Engineering News

Indevus Announces Second Quarter Fiscal 2006 Financial Results ...  May 8, 2006
..."We completed enrollment in both Phase III clinical trials for SANCTURA XR(TM) as well as our Phase II pagoclone trial for stuttering. ... - Genetic Engineering News

Indevus Pharma credits healthier drug sales for Q2 boost  May 9, 2006
...company said revenue was $14.4 million, up from $9.3 million in the second quarter of 2005, primarily driven by sales and royalties of Sanctura, a treatment ... - San Antonio Business Journal

Indevus Pharmaceuticals to Announce Second Quarter Fiscal 2006 ...  May 2, 2006
The Company currently markets SANCTURA® for overactive bladder and DELATESTRYL® for the treatment of male hypogonadism. The Company ... - Market Wire

Tricare co-pay to increase for six brand-name drugs  Apr 26, 2006
The new prices for these medications will take effect July 26. • Detrol, Oxytrol and Sanctura, used to treat overactive bladder conditions. ... - ArmyTimes.com





Indevus Pharmaceuticals Appoints New Board Member; Company ...  11 Apr 2006
The Company currently markets SANCTURA(R) for overactive bladder and DELATESTRYL(R) for the treatment of male hypogonadism. The ... - Business Wire

Indevus Completes Enrollment in Second Phase III Trial for ...  Mar 21, 2006
Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today reported that enrollment has been completed in the Company's second Phase III trial for SANCTURA XR. ... - Genetic Engineering News

Indevus completes enrollment in second late phase trial  Mar 23, 2006
Biopharmaceutical company Indevus Pharmaceuticals has completed enrollment in its second phase III trial for Sanctura XR, the company's once-daily formulation ... - Pharmaceutical Business Review

Indevus advances stuttering and incontinence programs  Mar 7, 2006
...trial for pagoclone, which is in development for stuttering, and in the first of its two ongoing phase III trials for overactive bladder treatment Sanctura XR. ... - Pharmaceutical Business Review

Pliva’s transition to generics proves painful  Mar 10, 2006
The firm also has bitter memories from its incontinence drug Sanctura, whose failure to turn a profit in the US forced the company to divest it last May. ... - In-PharmaTechnologist.com

Esprit Pharma Secures $50 Million Credit Facility, Further ...  Mar 30, 2006
Esprit first implemented this growth strategy in June 2005 with the acquisition of marketing rights to SANCTURA(R), a treatment for over-active bladder. ... - Genetic Engineering News



Indevus Pharma Completes Enrollment For Pagoclone - Quick Facts  07 Mar 2006
...has been completed in its Phase II trial for pagoclone, in development for stuttering, and the first of its two ongoing Phase III trials for SANCTURA XR. ... - Trading Markets,

Indevus Pharmaceuticals to Announce First Quarter Fiscal 2006 ...  Feb 2, 2006
The Company currently markets SANCTURA(R) for overactive bladder and DELATESTRYL(R) for the treatment of male hypogonadism. The ... - Genetic Engineering News,

UPDATE 2-Pliva buys Novartis generics unit in Spain  Feb 15, 2006
Pliva decided last year to exit proprietary business with the sale of its incontinence drug Sanctura, which according to some estimates incurred losses of more ... - Reuters

Esprit Pharma Expands Relationship with Dendrite; Dendrite's ...  Feb 15, 2006
...including Validator(TM) data-cleansing services andWebForce(TM) Express for its sales force, to help drive more targetedmarketing and sales of SANCTURA(R), an ... - Finanzen.net,

Pliva drops its German plant  Feb 3, 2006
The main culprit for this slump was its incontinence drug Sanctura, whose failure to make profit in the US plunged the company into considerable debt, so Pliva ... - In-PharmaTechnologist.com,

Indevus Pharmaceuticals Announces First Quarter Fiscal 2006 ...  09 Feb 2006
..."Our salesforce is now actively promoting DELATESTRYL(R) in addition to SANCTURA(R) and we have four products in Phase II or Phase III development.". ... - Genetic Engineering News

Indevus Pharmaceuticals to Announce First Quarter Fiscal 2006 ...  Feb 2, 2006
The Company currently markets SANCTURA(R) for overactive bladder and DELATESTRYL(R) for the treatment of male hypogonadism. The ... - Genetic Engineering News

Pliva drops its German plant  Feb 3, 2006
The main culprit for this slump was its incontinence drug Sanctura, whose failure to make profit in the US plunged the company into considerable debt, so Pliva ... - In-PharmaTechnologist.com

Pliva sells German plant to Italy's Menarini Group  Jan 26, 2006
...compared with a net profit of $107 million a year before, reflecting the costs incurred by loss-making proprietary incontinence drug Sanctura, which Pliva ... - Reuters

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional